Silo Pharma (SILO) announced that the Japan Patent Office has granted patent number 7683882 to Silo’s research and licensing partner Columbia University for the invention titled “Prophylactic efficacy of serotonin 4 receptor agonists against stress,” exclusively licensed to Silo by Columbia University. Columbia University recently received an Australian patent for the same invention. The patent reinforces protection for Silo’s lead asset, SPC-15, an intranasal treatment targeting post-traumatic stress disorder, originally developed by Columbia University.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SILO:
- Psychedelic: Bright Minds reports preclinical BMB-201 results
- Silo Pharma secures Australian patent covering licensed PTSD drug candidate
- Psychedelic: NRx Pharmaceuticals reports Q2 earnings
- Silo Pharma announces results for 7-day large animal safety study of SPC-15
- Silo Pharma Launches Cryptocurrency Advisory Board